Paratek Signs an Exclusive License Agreement with Almirall for SEYSARA (sarecycline)

 Paratek Signs an Exclusive License Agreement with Almirall for SEYSARA (sarecycline)

Paratek Reports Results of Nuzyra (omadacycline) in P-III OASIS-2 Study for Skin Infections

Shots:

  • Paratek to get exclusive rights to develop and commercialize sarecycline and will receive royalties on net sales of the product in the greater China region. Additionally, the companies are developing the product for ROW with profit split. Almirall to get rights to SEYSARA for acne in the US
  • In Mar 2017, Paratek granted exclusive the US rights of SEYSARA to Allergan. In 2018, Almirall acquired dermatology business portfolio including SEYSARA from Allergan
  • SEYSARA (sarecycline) is a once daily oral therapy targeted for the treatment of moderate to severe acne vulgaris. Almirall plans to develop the product in China for acne with NDA submission to the NMPA in 2023

Click here to read full press release/ article | Ref: Globe News wire | Image: Twitter

Shiwani Sharma

Shiwani Sharma is a Senior Editor at PharmaShots. She has in-depth knowledge of lifesciences industry including pharma and biotech sectors. She also covers news in field of Digital Health, Medtech and regulatory approvals from the US FDA, EU, and other global regulatory bodies in the industry. Additionally, she also writes Whitepapers, analysis reports, blogs on pharma and biotech industry. She is graduate in Biotechnology. She can be contacted on shiwani@pharmashots.com

Related post